SINTX Technologies (SINT) announced the execution of a private label agreement to supply OsseoSculpt, a next-generation biologic designed to complement the Company’s FDA 510(K) cleared SINAPTIC Foot & Ankle Osteotomy Wedge System. Following successful evaluations by multiple design surgeons, SINTX recorded its first commercial revenue from OsseoSculpt in Q3 2025. OsseoSculpt features a nanocrystalline HCA surface with a biomimetic pore architecture that provides an enhanced osteoconductive scaffold. SINTX will market this biologic alongside its SINAPTIC wedge system to augment bone healing in indicated procedures, providing surgeons with a streamlined solution from a single supplier. Commercial plan & near-term milestones: Limited release now through select design and early-adopter sites. Broader U.S. rollout aligned with wedge availability and surgeon training cycles through Q4 2025-Q1 2026. Growth drivers include: targeted in-service education, case support, and data capture on attach rate, procedure time, and outcomes for evidence-driven adoption.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SINT:
- Sintx Technologies files to sell 1.74M shares of common stock for holders
- Sintx receives FDA clearance for SINAPTIC Foot, Ankle implant system
- Sintx Technologies announces U.S. patent notice of allowance
- Sintx Technologies Announces At The Market Offering
- Sintx Technologies files to sell 541,450 shares of common stock for holders